Septerna FY2025 EPS Estimate Increased by Cantor Fitzgerald

Septerna, Inc. (NASDAQ:SEPN) – Equities researchers at Cantor Fitzgerald lifted their FY2025 earnings estimates for Septerna in a note issued to investors on Monday, May 19th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will earn ($0.14) per share for the year, up from their previous estimate of ($2.01). Cantor Fitzgerald currently has a “Overweight” rating and a $25.00 target price on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share.

Septerna (NASDAQ:SEPN) last issued its earnings results on Thursday, May 15th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). The firm had revenue of $0.22 million for the quarter.

Separately, Wells Fargo & Company raised their price target on shares of Septerna from $11.00 to $18.00 and gave the company an “equal weight” rating in a report on Friday, May 16th.

Septerna Price Performance

NASDAQ SEPN opened at $9.42 on Wednesday. The company’s 50-day simple moving average is $6.55 and its two-hundred day simple moving average is $14.05. Septerna has a one year low of $4.17 and a one year high of $28.99.

Hedge Funds Weigh In On Septerna

A number of large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC purchased a new stake in shares of Septerna in the fourth quarter valued at approximately $25,000. New York State Common Retirement Fund purchased a new stake in Septerna in the fourth quarter valued at approximately $32,000. Legal & General Group Plc acquired a new position in Septerna during the 4th quarter worth about $42,000. Summit Investment Advisors Inc. acquired a new stake in shares of Septerna during the fourth quarter worth about $45,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Septerna in the fourth quarter valued at approximately $52,000.

Insider Buying and Selling

In other Septerna news, Director Alan Ezekowitz purchased 41,355 shares of the business’s stock in a transaction that occurred on Thursday, March 6th. The shares were bought at an average price of $6.00 per share, for a total transaction of $248,130.00. Following the acquisition, the director now owns 104,101 shares in the company, valued at $624,606. This represents a 65.91% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Gil M. Labrucherie acquired 6,282 shares of the firm’s stock in a transaction on Tuesday, February 25th. The shares were acquired at an average price of $5.59 per share, with a total value of $35,116.38. Following the completion of the purchase, the chief financial officer now owns 36,282 shares in the company, valued at approximately $202,816.38. This trade represents a 20.94% increase in their position. The disclosure for this purchase can be found here. Insiders bought 63,846 shares of company stock valued at $381,815 over the last quarter. 4.30% of the stock is currently owned by company insiders.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.